Examples include the exoASOTM platform from Codiak BioSciences, which targets transcriptional regulators like STAT6 in tumor-associated macrophages [116], and Evox Therapeutics’ genome-editing exosomes, developed for disorders like Spinocerebellar Ataxia 2 and Huntington’s disease [111]. The gene discussed is STAT6; the disease is spinocerebellar ataxia type 2.